2-(4-morpholinoanilino)-6-cyclohexylaminopurine has been researched along with interleukin-8 in 1 studies
| Studies (2-(4-morpholinoanilino)-6-cyclohexylaminopurine) | Trials (2-(4-morpholinoanilino)-6-cyclohexylaminopurine) | Recent Studies (post-2010) (2-(4-morpholinoanilino)-6-cyclohexylaminopurine) | Studies (interleukin-8) | Trials (interleukin-8) | Recent Studies (post-2010) (interleukin-8) |
|---|---|---|---|---|---|
| 85 | 0 | 62 | 23,523 | 1,167 | 9,990 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, JM; Kwon, KB; Lee, YR; Noh, EM; Song, HK; You, YO | 1 |
1 other study(ies) available for 2-(4-morpholinoanilino)-6-cyclohexylaminopurine and interleukin-8
| Article | Year |
|---|---|
Reversine inhibits MMP-3, IL-6 and IL-8 expression through suppression of ROS and JNK/AP-1 activation in interleukin-1β-stimulated human gingival fibroblasts.
Topics: Fibroblasts; Gingiva; Humans; Interleukin-1beta; Interleukin-6; Interleukin-8; MAP Kinase Kinase 4; Matrix Metalloproteinase 3; Morpholines; NF-kappa B; Periodontitis; Purines; Reactive Oxygen Species; Transcription Factor AP-1 | 2019 |